Jennifer Costello, PharmD, BCPS, BC-ADM

	This activity is supported by an educational grant from 

Overcoming Patient Barriers in Glycemic Control: Clinical Advances in Combination GLP-1 and Insulin Therapy

		High Lakes Health Care Executive Director and Co-founder,

		Jennifer Costello, PharmD, BCPS, BC-ADM

		Assistant Director of Clinical Services for the Pharmacy Department

	After completing this continuing education program, the participant will be able to:

		Examine the glycemic control treatment gap in patients with type 2 diabetes and the factors that contribute to poor glycemic control

		Explain the use of combination regimens as initial treatment of type 2 diabetes to improve glycemic control

		Analyze the efficacy and safety of prandial insulin and glucagon-like peptide-1 (GLP-1) receptor agonists (both short-and long-acting) in combination with basal insulin, including the use of injectable coformulations

		Explore the role of the pharmacist in collaborating with clinicians and educating patients about GLP-1 agonists in combination with basal insulin and measures taken to decrease diabetic complications and promote adherence

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-16-079-H01-P. The activity is available for CE credit through June 12, 2017.

Articles

This Continuing Education activity is supported by an educational grant from sanofi-aventis U.S.

	This activity is supported by an educational grant from AstraZeneca LP and Novo Nordisk, Inc

Redefining the Management of Diabetes: A Review of Quality and Individualizing Patient Care

		Review clinical practice guidelines and standards of care in the management of type 2 diabetes mellitus.

		Examine comprehensive treatment plans for patients with diabetes that focus on individualization.

		Document recommendations, benefits, risks, limitations, and controversies surrounding pharmacologic therapy with insulin.

		Adopt programs focused on achieving clinical metrics and improving patient outcomes.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. 

This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-15-050-H01-P. The activity is available for CE credit through June 7, 2017.

This Continuing Education activity is supported by an educational grant from AstraZeneca LP and Novo Nordisk, Inc

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Examining New Treatment Strategies Aimed at Stroke Prevention in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

The following contributors have no relevant financial relationships with commercial interests to disclose

Office of Continuing Professional Education

David Heckard; Steve Lin, PharmD, RPh; Maryjo Dixon, RPh; and Donna Fausak

An anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

At the conclusion of this educational activity, participants should be able to:

		Discuss the prevalence, epidemiology, and risk of stroke in patients with atrial fibrillation (AF).

		Explore the underrecognized risk of stroke and inadequate prophylaxis in patients with AF.

		Examine current guidelines, with respect to risk stratification recommendations for appropriate anticoagulation, and impact on patient outcomes.

		Review newly approved oral anticoagulants and identify their practice-focused differences from warfarin and their role in stroke prevention.

		Explore the pharmacist’s role in educating patients on the risk of stroke in AF, monitoring anticoagulation therapy, and participating in disease management opportunities.

This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-015-H01-P. The activity is available for CE credit through March 12, 2016.

Pharmacists can learn about educating patients on the risk of stroke in atrial fibrillation, monitoring anticoagulation therapy, and participating in disease management opportunities.